Mechanism-Based Inactivation of Cytochromes P450 2B1 and P450 2B6 by n-Propylxanthate
- 12 March 1999
- journal article
- research article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 12 (4) , 317-322
- https://doi.org/10.1021/tx9802421
Abstract
n-Propylxanthate (nPX) inactivated the 7-ethoxy-4-(trifluoromethyl)coumarin (7-EFC) O-deethylation activity of purified, reconstituted rat hepatic P450 2B1 or human P450 2B6 in a mechanism-based manner. The inactivation followed pseudo-first-order kinetics and was entirely dependent on both NADPH and nPX. The maximal rate constant for inactivation of P450 2B1 at 30 °C was 0.2 min-1. The apparent KI was 44 μM, and the half-time for inactivation was 4.1 min. Purified, reconstituted human P450 2B6 was also inactivated by nPX with a KI of 12 μM. The kinactivation for P450 2B6 was 0.06 min-1, and the t1/2 was 11 min. Incubations of P450 2B1 with nPX and NADPH for 20 min resulted in a 75% loss in enzymatic activity and a concurrent 25% loss of the enzyme's ability to form a reduced CO complex. Little loss in the absolute spectrum of nPX-inactivated P450 2B1 was observed. With P450 2B6, an 83% loss in enzymatic activity and a 12% loss in the CO-reduced spectra were observed. The extrapolated partition ratio for nPX with P450 2B1 was 32. P450 2B1 could be protected from inactivation by nPX by adding an alternate substrate to the reaction mixture. Removal of unbound nPX by dialysis did not reverse the inactivation. The alternate oxidant iodosobenzene was able to partially restore enzymatic activity to nPX-inactivated P450 2B1 samples. A stoichiometry for labeling of 1.2:1 for binding of radiolabeled nPX metabolite to P450 2B1 was seen. These results indicated that nPX inactivated P450 2B1 and P450 2B6 in a mechanism-based manner. P450 2B1 was inactivated primarily by a nPX reactive intermediate that bound to the apoprotein.Keywords
This publication has 11 references indexed in Scilit:
- High-resolution crystal structure of cytochrome P450camPublished by Elsevier ,2005
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- Structural Basis of Selective Cytochrome P450 InhibitionAnnual Review of Pharmacology and Toxicology, 1995
- Crystal structure and refinement of cytochrome P450terp at 2·3 Å resolutionJournal of Molecular Biology, 1994
- Genotoxicity of tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450sCarcinogenesis: Integrative Cancer Research, 1994
- Upregulation of Estradiol C16 -hydroxylation in Human Breast Tissue: a Potential Biomarker of Breast Cancer RiskJNCI Journal of the National Cancer Institute, 1993
- cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liverBiochemistry, 1989
- Measurement of protein using bicinchoninic acidAnalytical Biochemistry, 1985
- Effects of potassium ethylxanthogenate and 2,3-dimercaptopropane sulphonate sodium on the pentobarbital pharmacokinetics and metabolism in male miceEuropean Journal of Drug Metabolism and Pharmacokinetics, 1982
- Purification to homogeneity and characterization of a form of cytochrome P-450 with high specificity for benzo[alpha]pyrene from beta-naphthoflavone-pretreated rat liver microsomes.Journal of Biological Chemistry, 1981